Abstract | BACKGROUND: METHODS AND RESULTS: Intravascular thrombosis was obtained by placing an external constrictor around carotid arteries with endothelial injury. Carotid blood flow velocity ws measured continuously with a Doppler flow probe. Thirty minutes after thrombus formation, the rabbits received either AP-1 (0.15 mg/kg IV, n=8) or placebo (n=8). All rabbits also received TPA (80 microg/kg bolus plus 8 microg x kg(-1) x min(-1) infusion for up to 90 minutes or until reperfusion was achieved) and heparin (200 U/kg IV as a bolus). At reperfusion, TPA was discontinued, and the rabbits were followed for an additional 90 minutes. AP-1 shortened lysis time from 44+/-8 minutes (mean+/-SEM) in control rabbits to 26+/-7 minutes in AP-1 rabbits (P<.01). Reocclusion occurred in all control rabbits in 10+/-3 minutes, whereas it occurred in only two of eight AP-1 treated rabbits in 72 and 55 minutes (P<.01). No changes in prothrombin time and ex vivo platelet aggregation in response to various agonists were observed after AP-1 administration, indicating the absence of systemic effects by this antibody. CONCLUSIONS: TF exposure and activation of the extrinsic coagulation pathway play an important role in prolonging lysis time and mediating reocclusion after thrombolysis in this model. AP-1, a monoclonal antibody against TF, might be suitable as adjunctive therapy to TPA.
|
Authors | M Ragni, P Cirillo, I Pascucci, A Scognamiglio, D D'Andrea, N Eramo, M D Ezekowitz, A B Pawashe, M Chiariello, P Golino |
Journal | Circulation
(Circulation)
Vol. 93
Issue 10
Pg. 1913-8
(May 15 1996)
ISSN: 0009-7322 [Print] United States |
PMID | 8635271
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Fibrinopeptide A
- Fibrinogen
- Thromboplastin
- Plasminogen Activators
- Tissue Plasminogen Activator
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Carotid Artery Thrombosis
(therapy)
- Female
- Fibrinogen
(analysis)
- Fibrinopeptide A
(analysis)
- Male
- Plasminogen Activators
(therapeutic use)
- Platelet Aggregation
- Rabbits
- Thromboplastin
(physiology)
- Tissue Plasminogen Activator
(pharmacology)
|